Table 3.
Comparison of clinical factors between 4F2hc Low and 4F2hc High groups.
| 4F2hc Low | 4F2hc High | P | ||
|---|---|---|---|---|
| Age (y) | 64.50 ± 5.25 | 66.50 ± 5.20 | 0.0162 | * |
| cT stage (n) | 0.0255 | * | ||
| 1 | 29 | 25 | ||
| 2 | 5 | 8 | ||
| 3 | 2 | 9 | ||
| GS (n) | 0.0035 | * | ||
| 6 | 17 | 7 | ||
| 7 | 19 | 18 | ||
| 8 | 3 | 9 | ||
| 9 | 1 | 8 | ||
| TST (ng/dL) | 4.66 ± 1.92 | 4.64 ± 1.78 | 0.1661 | |
| PSA (ng/mL) | 7.46 ± 6.37 | 8.30 ± 6.57 | 0.3781 | |
| PSAD | 0.27 ± 0.23 | 0.30 ± 0.31 | 0.1156 |
Data are expressed as means ± standard deviation unless otherwise indicated. cT stage = clinical tumour stage, GS = Gleason score, TST = testosterone, PSA = prostate-specific antigen, PSAD = PSA density.
*Statistical significance (p < 0.05).